Julien Rongère
Consigliere Generale presso AC IMMUNE SA
Posizioni attive di Julien Rongère
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| AC IMMUNE SA | Consigliere Generale | 01/07/2017 | - |
Storia della carriera di Julien Rongère
Precedenti posizioni note di Julien Rongère
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Apoxis SA
 Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland. | Corporate Officer/Principal | - | - |
Celgene Switzerland SARL
 Celgene Switzerland SARL Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Switzerland SARL is a Swiss biopharmaceutical company. The company is based in Boudry, Switzerland. | Consigliere Generale | - | - |
Formazione di Julien Rongère
| University of Aberdeen | Graduate Degree |
| University of Lausanne | Doctorate Degree |
Statistiche
Distribuzione geografica
| Svizzera | 5 |
| Regno Unito | 2 |
Posizioni
| General Counsel | 2 |
| Graduate Degree | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Aziende private | 2 |
|---|---|
Apoxis SA
Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland. | Health Technology |
Celgene Switzerland SARL
Celgene Switzerland SARL Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Switzerland SARL is a Swiss biopharmaceutical company. The company is based in Boudry, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- Julien Rongère
- Esperienza
